Apr 30, 2018
FLINT, Mich. — April 30, 2018 — The nation’s largest independent provider of specialty pharmacy services unites benefit-management companies to form specialty-focused CastiaRx.
Diplomat Pharmacy, Inc. (NYSE: DPLO), has unveiled CastiaRx to respond to industry demand for a leader in specialty benefit management.
CastiaRx unites the full-service pharmacy benefit manager (PBM) capabilities of recently acquired LDI Integrated Pharmacy Services and National Pharmaceutical Services with Diplomat’s specialty pharmacy and infusion expertise.
According to the the IQVIA Institute for Human Data Science, the late-phase development pipeline recently included more than 800 specialty drugs. The Pharmacy Benefit Management Instituteprojects that more than 50 percent of U.S. drug spend will be specialty by 2020.
Albert Thigpen, president and chief operating officer of CastiaRx, said specialty drugs are life-changing for people with complex diseases—including cancer and rare genetic conditions—but often require more expert support.
“The current PBM model wasn’t designed to address the challenges that come with specialty drugs,” Thigpen said. “While CastiaRx offers traditional PBM services, we also bring broader depth to address the intricacies of specialty pharmacy management—under both the pharmacy and medical benefit. With 24/7 patient support, advanced analytic capabilities, and clinical expertise founded on a centers-of-excellence approach, we can help patients achieve the best possible outcomes.”
Joel Saban, president of Diplomat, said CastiaRx simplifies the patient journey by tailoring support based on the patient’s stage of illness, clinical status, and communication preferences. He said the brand focuses on anticipating member needs, increasing adherence, closing gaps in care, and ultimately enabling better outcomes. CastiaRx offers a range of service levels, with high-touch support for patients who need it and digital tools for those who prefer self-service.
“Managing specialty drug spend is part of our company’s DNA,” Saban said. “We saw tremendous synergies between Diplomat’s longstanding efforts in this area and those of our PBMs. Uniting all this under CastiaRx can relieve the complexity of specialty drug management for small and midsize payers as we provide a true solution to help them prepare for what’s ahead.”
CastiaRx combines 50 years of PBM service with more than 40 years’ experience handling specialty pharmaceuticals.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance and may include Diplomat’s expectations regarding benefits of business and growth strategies. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. These risks and uncertainties include: our ability to adapt to changes or trends within the specialty pharmacy industry; increasing consolidation in the healthcare industry; our ability to successfully integrate acquired businesses; and the additional factors set forth in “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended Dec. 31, 2017, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) is the nation’s largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payers, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.
CastiaRx is the industry’s leading specialty benefit manager. Combining full-service pharmacy benefit manager capabilities with specialty expertise, CastiaRx addresses spend across the benefit spectrum. The company leads with compassion, striving to simplify specialty management for its partners. Believe in better with CastiaRx—better treatment, better care, and a better path to a healthier future. For more information, visit castiarx.com.
|Dec 11, 2018||Jorgenson Issues Annual List of Major Challenges Facing Hospital and Health Syst...|
|Nov 29, 2018||BD Expands Integrated Medication Management to Help Tackle Hospital Drug Diversi...|
|Nov 13, 2018||Akro-Mils 2019 Catalog|
|Nov 13, 2018||New Data Shows Many Health System Pharmacies Considering Consolidated Distributi...|
|Oct 17, 2018||Retail Management Solutions Celebrates 20 Years of Pharmacy POS Innovation|
|Oct 17, 2018||Hardy Diagnostics Releases a New Locking Lid Feature for all Contact Plates|
|Oct 15, 2018||Transaction Data Systems Partners with Community Pharmacies to Fight the Opioid ...|
|Oct 12, 2018||1st Patient-Centered Respiratory Home™ Accreditation Recipient Named|
|Oct 10, 2018||Augusta University Health Selects Omnicell’s Industry-Leading Medication Manag...|
|Oct 04, 2018||QS/1® Honors Pharmacists at NCPA|
|Oct 03, 2018||Innovation to Move to New Campus in New York’s Southern Tier to Accommodate St...|
|Oct 03, 2018||Equashield and Max Care Medical to Distribute Leading Closed System Transfer Dev...|
|Oct 01, 2018||Global Needlefree Closed System Transfer Device (CSTD) Market 2018 by Manufactur...|
|Sep 23, 2018||Prudential Overall Supply Celebrates Dan Clark's 50th Employment Anniversary|
|Sep 19, 2018||RXQ Compounding Expanding in Albany|
|Sep 17, 2018||Middlesex Hospital Bolsters Pharmacy Safety and Compliance by Extending Wolters ...|
|Sep 14, 2018||Synergy Medical once again among Canada's Top 500 Companies|
|Sep 10, 2018||American Associated Pharmacies Taps FDS to Bring its Members a State-of-the-Art ...|
|Sep 10, 2018||Rees Scientific achieved ISO/IEC 17025:2017 Accreditation|
|Sep 06, 2018||Medical Packaging Inc. Named One of The Best Places to Work In New Jersey|
|Sep 06, 2018||Americorp Financial Launches New Brand, Website for Equipment Financing|
|Sep 04, 2018||Excelera® Specialty Pharmacy Network Announces Partnership with Smith & Nephew|
|Aug 30, 2018||Letco Medical, L.L.C. Announces Exclusive Partnership with Sweetgrass GxP Group,...|
|Aug 29, 2018||QS/1® Selected as Early Adopter in New CMS SCRIPT Standard|
|Aug 23, 2018||Innovations to Omnicell Patient Engagement Platform Support Value-Based, Patient...|
|Aug 14, 2018||ACHC and ExceleraRx Corp. Form Partnership|
|Aug 13, 2018||RetailSTARx with McKesson’s EnterpriseRx Supports ID Tracking for Controlled S...|
|Aug 07, 2018||Fagron, Inc. Announces New Hair Care Line - TrichoConcept™|
|Aug 03, 2018||Letco Medical, L.L.C. Launches Pharmacy Financial Services to Support Compoundin...|
|Aug 02, 2018||Beaumont Health Selects Omnicell’s Medication Management Platform and Services...|
Connect with thousands of pharmacy professionals throughout every practice setting.